Springer Nature
Browse
12943_2024_1942_MOESM1_ESM.doc (837 kB)

Additional file 1 of Impact of metronomic trabectedin combined with low-dose cyclophosphamide on sarcoma microenvironment and correlation with clinical outcome: results from the TARMIC study

Download (837 kB)
journal contribution
posted on 2024-02-20, 04:40 authored by Cheng-Ming Sun, Maud Toulmonde, Mariella Spalato-Ceruso, Florent Peyraud, Alban Bessede, Michèle Kind, Sophie Cousin, Xavier Buy, Jean Palussiere, Antoine Bougouin, Catherine Sautès-Fridman, Hervé Wolf Fridman, Marina Pulido, Antoine Italiano
Supplementary Material 1

Funding

PharmaMar

History

Usage metrics

    Molecular Cancer

    Categories

    Keywords

    first prospective evidencediverse mesenchymal tumorsimproved clinical benefitclinical data suggesttumor lesions comparedcell presence increased50 patients participatedreduced m2 macrophagesmetronomic trabectedin combinedii results evaluatingadvanced sts patientsclinical outcometumor microenvironmentmetronomic trabectedinincreased cd8advanced stagesadvanced sarcomaspatients exhibited28 patientstumoral functionstrabectedin ’therapeutic optionssarcoma microenvironmentpositive shiftphase iipatient outcomesnumber nct02406781immunological effectglobal approvalfree survivaldose cyclophosphamideday twocells postbased regimensassociated macrophages4 weeks

    Licence

    CC BY + CC0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC